2022
Severe inpatient hypertension prevalence and blood pressure response to antihypertensive treatment
Ghazi L, Li F, Chen X, Simonov M, Yamamoto Y, Biswas A, Hanna J, Shah T, Townsend R, Peixoto A, Wilson FP. Severe inpatient hypertension prevalence and blood pressure response to antihypertensive treatment. Journal Of Clinical Hypertension 2022, 24: 339-349. PMID: 35174627, PMCID: PMC8925013, DOI: 10.1111/jch.14431.Peer-Reviewed Original ResearchConceptsSevere hypertensionBlood pressure responseBP elevationUntreated patientsCox proportional hazards modelRetrospective cohort studyPressure responseProportional hazards modelAntihypertensive treatmentInpatient hypertensionMore comorbiditiesPossible overtreatmentHospitalized adultsCohort studyHypertension prevalenceArterial pressureHospitalized patientsTreatment guidelinesHypertensionGreater rateHazards modelPatientsAntihypertensivesTreatmentAdmission
2017
Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study
Assel MJ, Li F, Wang Y, Allen AS, Baggerly KA, Vickers AJ. Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study. Ophthalmology 2017, 125: 391-397. PMID: 29032853, PMCID: PMC5820191, DOI: 10.1016/j.ophtha.2017.09.008.Peer-Reviewed Original ResearchConceptsAge-related macular degenerationAdvanced age-related macular degenerationEye Disease StudyGenotype-treatment interactionDisease StudyHigh-risk patientsStandard careAMD progressionBaseline predictorsMacular degenerationTreatment responseGenotype subgroupsAREDS participantsPatientsGenetic polymorphismsSingle nucleotide polymorphismsCategory 1Negative resultsAgePopulation of interestTreatmentMultiple testingProgressionNucleotide polymorphismsAntioxidants